ArticleJournal of comparative effectiveness research2026

Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison.

Todd Bauer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.